Temozolomide Followed by Ipilimumab and Nivolumab for Microsatellite-Stable, MGMT-Silenced Metastatic CRC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
J. Clin. Oncol 2022 Mar 08;[EPub Ahead of Print], F Morano, A Raimondi, F Pagani, S Lonardi, L Salvatore, C Cremolini, S Murgioni, G Randon, F Palermo, L Antonuzzo, N Pella, P Racca, M Prisciandaro, M Niger, F Corti, F Bergamo, A Zaniboni, M Ratti, M Palazzo, C Cagnazzo, MA Calegari, F Marmorino, I Capone, E Conca, A Busico, S Brich, E Tamborini, F Perrone, M Di Maio, M Milione, M Di Bartolomeo, F de Braud, F PietrantonioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.